id,disease_progression_status,survival_status,clinical_response_rate_target_lasion,clinical_response_rate_non_target_lasion,clinical_response_rate_new_lasion,clinical_response_rate_result,radiological_response_rate_target_lasion,radiological_response_rate_non_target_lasion,radiological_response_rate_new_lasion,radiological_response_rate_result,pathological_response_rate_target_lasion,pathological_response_rate_non_target_lasion,pathological_response_rate_new_lasion,pathological_response_rate_result,time,registration_number,laterality,current_chemo_protocol,chemo_starting_date,chemo_cycle_no,chemo_detail,disease_progression_status_date,pfs,survival_status_date,overall_survival,clinical_response_rate_date,radiological_response_rate_date,pathological_response_rate_date,cancer_type,patient_id_id,patient_id_socio_economic_status_name,patient_id_unique_id,patient_id_name,patient_id_phone,patient_id_date_of_birth,patient_id_gender,patient_id_blood_group,patient_id_area,patient_id_police_station,patient_id_district,doctor_id_name,center_id_name,grade_name,line_of_treatment_name,diagnosis_disease_group_name,diagnosis_subgroup_diagnosis_disease_group_name,diagnosis_subgroup_name,diagnosis_primary_site_name,diagnosis_laterility_name,patient_id_socio_economic_status,grade,disease_progression_status_name,survival_status_name,clinical_response_rate_target_lasion_name,clinical_response_rate_non_target_lasion_name,clinical_response_rate_new_lasion_name,clinical_response_rate_result_name,radiological_response_rate_target_lasion_name,radiological_response_rate_non_target_lasion_name,radiological_response_rate_new_lasion_name,radiological_response_rate_result_name,diagnosis_laterility,line_of_treatment,diagnosis_subgroup,pathological_response_rate_target_lasion_name,pathological_response_rate_non_target_lasion_name,pathological_response_rate_new_lasion_name,pathological_response_rate_result_name,diagnosis_disease_group,diagnosis_primary_site,name,value,unit,date,patient_observation_id
57,,,,,,,,,,,,,,,2024-05-06T14:09:33+06:00,BSH - H12203238617,Left,Trastuzumab,2023-03-18,,"Started ADCT with TCH from 21.03.22. Cycle 5 is due on 16.06.22 (Received on 21.06.22
and hospitalized due to COVID), C6 due on 13.07.22 (TCH- postponed and only Herceptin given on 26.07.22
as maintenance-1), Completed Maintenance 12 Trastuzumab on 18.03.2023",2023-10-01,,2024-03-06,,2023-09-27,,,Breast,54,Upper middle class,BSBSC-240000054,REBEKA SULTANA,1816194986,1956-02-11,Female,,,,,Dr Ferdous Ara Begum,BSH,2.0,Continuous Maintenance,C50- Malignant neoplasm of breast,C50- Malignant neoplasm of breast,C50.2- Upper-inner quadrant of breast,Breast,Left,,,Stable,Alive,CR,,,,,,,,,,,,,,,,,,,,,
